RxDoctor Payments Data

Joseph Clever, MD

Ophthalmology · St Charles, MONPI 1245438886

Payments from drug & device makers

$3,523in general payments, 2019–2025

Across 104 payments — averaging $33.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Tarsus Pharmaceuticals, Inc.$387
  • AbbVie$385
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$225
  • Bausch & Lomb Americas Inc.$216
  • Aerie Pharmaceuticals, Inc.$173
  • plus $834 from 13 others

What the payments were for

  • Food & beverage$3,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,523 in reported general payments places this provider in the 60th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$355,246
Medicare patients
973
Services billed
3,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BesivanceBesifloxacin Hcl303$67,613
ProlensaBromfenac Sodium185$64,259
RestasisCyclosporine33$45,470
LumiganBimatoprost82$38,716
Bromfenac Sodium118$29,430
Prednisolone Acetate696$17,394
Cyclosporine22$12,317
Ketorolac Tromethamine454$9,189
MoxifloxacinMoxifloxacin Hcl315$7,512
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$7,028
Alphagan PBrimonidine Tartrate15$6,063
CombiganBrimonidine Tartrate/Timolol14$5,581
Brimonidine Tartrate30$5,357
Timolol Maleate124$5,186
Latanoprost481$4,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa$225$131,872488 claims
AbbVieRestasis, Lumigan, Alphagan P, Combigan$385$95,831144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 286 ophthalmology providers in Missouri.

Other ophthalmology in St Charles

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →